STOCK TITAN

Baselake Partners discloses 9.7% Synlogic (SYBX) position on Schedule 13G

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Synlogic, Inc. received a Schedule 13G reporting that investment entities affiliated with Baselake Partners, LP, including Baselake Management, LLC and individual investor David Paolella, beneficially own 1,140,000 shares of Synlogic common stock. This represents 9.7% of the outstanding common stock, based on the issuer’s report that 11,698,919 shares were outstanding as of November 6, 2025.

The shares are held by Baselake Partners, LP, with Baselake Management, LLC as investment manager and Paolella as managing member, and they report shared voting and dispositive power over all 1,140,000 shares and no sole voting or dispositive power. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Synlogic.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Please see note in Item 4(a)


SCHEDULE 13G




Comment for Type of Reporting Person: Please see note in Item 4(a)


SCHEDULE 13G




Comment for Type of Reporting Person: Please see note in Item 4(a)


SCHEDULE 13G



Baselake Partners, LP
Signature:/s/ David Paolella
Name/Title:David Paolella, Managing Member of Baselake Management, LLC, its investment manager
Date:01/23/2026
Baselake Management, LLC
Signature:/s/ David Paolella
Name/Title:David Paolella, Managing Member
Date:01/23/2026
David Paolella
Signature:/s/ David Paolella
Name/Title:Individually
Date:01/23/2026
Exhibit Information

Exhibit I - JOINT FILING STATEMENT

FAQ

What stake in Synlogic, Inc. (SYBX) does Baselake Partners report on this Schedule 13G?

The filing reports that Baselake Partners, LP and related reporting persons beneficially own 1,140,000 shares of Synlogic common stock, representing 9.7% of the class.

Who are the reporting persons on the Synlogic (SYBX) Schedule 13G?

The reporting persons are Baselake Partners, LP, Baselake Management, LLC, and David Paolella, who is the managing member of Baselake Management, LLC.

How is voting and dispositive power over Synlogic (SYBX) shares allocated among the Baselake reporting persons?

Each reporting person reports 0 shares with sole voting and dispositive power and 1,140,000 shares with shared voting and dispositive power.

What ownership percentage basis is used in the Baselake Schedule 13G for Synlogic (SYBX)?

The 9.7% ownership is calculated using Synlogic’s statement that 11,698,919 shares of common stock were issued and outstanding as of November 6, 2025.

Does the Baselake Schedule 13G state an intent to influence control of Synlogic (SYBX)?

The certification states that the securities were not acquired and are not held for the purpose of changing or influencing the control of Synlogic and are not held in connection with any such transaction, other than activities solely in connection with a nomination under Rule 240.14a-11.

What class of Synlogic (SYBX) securities is covered by this Schedule 13G?

The Schedule 13G covers common stock of Synlogic, Inc., with a par value of $0.001 per share, CUSIP 87166L209.
Synlogic

NASDAQ:SYBX

SYBX Rankings

SYBX Latest News

SYBX Latest SEC Filings

SYBX Stock Data

6.55M
10.34M
11.26%
64.65%
0.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
WINCHESTER